Cargando…

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538758/ https://www.ncbi.nlm.nih.gov/pubmed/26283632 http://dx.doi.org/10.1186/s13075-015-0721-3

Ejemplares similares

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
por: Spiera, Robert F, et al.
Publicado: (2011)

Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein
por: Shukla, Suneet, et al.
Publicado: (2014)

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
por: Chakravarty, Eliza F., et al.
Publicado: (2015)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms
por: Mahoney, J. Matthew, et al.
Publicado: (2015)

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis
por: Arron, Sarah T., et al.
Publicado: (2014)

Endocrine mucin-producing sweat gland carcinoma of the scalp treated with Mohs micrographic surgery
por: Navrazhina, Kristina, et al.
Publicado: (2018)

Identification of cell cycle–regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors
por: Grant, Gavin D., et al.
Publicado: (2013)

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
por: Taroni, Jaclyn N., et al.
Publicado: (2017)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature
por: Derrett-Smith, Emma C., et al.
Publicado: (2017)

Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis
por: Hinchcliff, Monique, et al.
Publicado: (2013)

Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures
por: Taroni, Jaclyn N., et al.
Publicado: (2015)

Regulator combinations identify systemic sclerosis patients with more severe disease
por: Wang, Yue, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies
por: Gordon, Jessica, et al.
Publicado: (2011)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Nicolau syndrome after lumbar puncture: A case report in a 22-month-old girl
por: Navrazhina, Kristina, et al.
Publicado: (2017)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
por: Airiau, K, et al.
Publicado: (2013)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis
por: Johnson, Michael E., et al.
Publicado: (2016)

Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin
por: Johnson, Michael E., et al.
Publicado: (2019)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation
por: Mehta, Bhaven K., et al.
Publicado: (2022)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma
por: Au, Karolyn, et al.
Publicado: (2015)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Recommendations for medical student preparedness and equity for dermatology residency applications during the COVID-19 pandemic
por: Stewart, Claire R., et al.
Publicado: (2020)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
por: Paramarta, Jacqueline E., et al.
Publicado: (2016)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

Hepatitis B Virus Reactivation under Treatment with Nilotinib
por: Temel, Tuncer, et al.
Publicado: (2015)

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
por: Contreras, Osvaldo, et al.
Publicado: (2018)

A Case of Severe, Nilotinib-Induced Liver Injury
por: Belopolsky, Yuliya, et al.
Publicado: (2019)

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
por: Turner, Raymond S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_clif14gjui3ceqhqsd3kou9k4c